Celator presents new data on CPX-351 liposome injection in European Hematology Association congress Celator Pharmaceuticals today announced that new data from a preclinical leukemia research in mice demonstrate that its lead item, CPX-351 Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the mix of either agent with the traditional cytarabine:daunorubicin routine without insurance . ‘As prior research has demonstrated, the task of merging cytarabine:daunorubicin with additional anti-leukemic agents is that the dosing modifications necessary to prevent unacceptable toxicities may compromise treatment efficacy,’ stated Lawrence Mayer, PhD, mind and president of research at Celator Pharmaceuticals.
The Encore partnership with Cedars-Sinai is targeted on enabling the health system to accomplish complete success in its CPOE implementation, putting the necessary tools in place to keep up such success for a long time to come. A specific objective of the project is certainly that Encore help Cedars-Sinai to attract and maintain an internal team been trained in skills and know-how which will reduce the usage of consultants over time. Encore and Cedars refer to this area of the partnership as ‘sustainability’ – a term describing the delivery of high provider amounts to Cedars’ stakeholders that are independent of third-party support after task completion. ‘At Cedars-Sinai, we’ll make sure that procedure redesign is incorporated with application features that support consumer adoption,’ said Dana Retailers, President and CEO, Encore Health Assets.